Cheapest compounded tirzepatide telehealth in 2026: the verified program list
Tirzepatide costs more than compounded semaglutide at most programs, but not all. Mochi Health charges a flat $178 a month for its compounded GLP-1 program regardless of molecule. Below that, the numbers come with catches: minimum commitments, pricing-at-signup opacity, or 12-month lock-ins. Plus the regulatory risk specific to tirzepatide that the semaglutide list does not carry.
The short answer. The cheapest flat injectable price we can confirm for compounded tirzepatide is Mochi Health at $178 a month. Mochi charges that same flat rate across all its compounded GLP-1 injections: the price does not climb when you titrate up or switch molecules. Ivim Health lists a slightly lower $175 a month, but requires a 4-month minimum commitment upfront. Below those two, the verified prices for tirzepatide specifically get messier: some programs charge more for tirzepatide than for their compounded semaglutide tier, and others show pricing only at signup.
Compounded tirzepatide also carries more regulatory risk than compounded semaglutide in 2026. The FDA declared the tirzepatide active ingredient shortage resolved in early 2025. That ruling narrowed the legal basis for broad 503A compounding, and Eli Lilly has filed litigation directly against compounding pharmacies. Two programs in our chart are named in that litigation. The risk matters when you are choosing a cash-pay program for a multi-month treatment course.
| Fact | Value | Source | Verified |
|---|---|---|---|
| Cheapest confirmed tirzepatide injectable (all-in, M2M) | $178/mo (Mochi Health, flat rate) | GLP Chart verified prices | 2026-06-12 |
| Cheapest raw price (requires 4-month min) | $175/mo (Ivim Health) | GLP Chart verified prices | 2026-06-12 |
| Programs offering compounded tirzepatide | 11 of 25 tracked | providers.json | 2026-06-12 |
| Tirzepatide trial weight loss (SURMOUNT-1, max dose) | ~21% mean body weight | SURMOUNT-1 (NEJM, 2022) | Published |
| Semaglutide trial weight loss for comparison (STEP-1, max dose) | ~15% mean body weight | STEP-1 (NEJM, 2021) | Published |
| Lilly litigation status | Active; programs named include Mochi and Found | Public court records, 2025 | 2026-06-12 |
The cheapest compounded tirzepatide programs, ranked
Prices are the all-in monthly cost from our chart, re-verified every Monday. Lock-in and regulatory exposure are from our scoring criteria. Click any program name for the full review.
| Program | Monthly all-in | Lock-in | Key caveat |
|---|---|---|---|
| Ivim Health | $175/mo | 4-month minimum | Lowest sticker price. Tirzepatide included in the compounded catalog at the verified rate. The 4-month minimum means $700 committed before you know how you tolerate the drug. |
| Mochi Health | $178/mo | Month-to-month | Flat pricing model: same $178 at every dose tier, both semaglutide and tirzepatide. No surprise increase at the maintenance dose. Named in Lilly's 2025 litigation; continues operations as of June 2026. |
| Henry Meds | $197/mo (reported) | Month-to-month | Pricing shown at signup only. The $197 is the reported tier from patient accounts; the tirzepatide-specific rate may differ. Transparency score is lower than Mochi or Ivim. |
| Found | $199/mo | 12-month commitment | Lowest published price that includes a full year. The 12-month commitment is the highest lock-in severity in this list. Named in Lilly litigation alongside Mochi. |
| Medvi | $299/mo (tirzepatide) | Month-to-month | Medvi charges $179/mo for compounded semaglutide and $299/mo for tirzepatide. No lock-in. The least expensive confirmed no-lock-in option if you want tirzepatide specifically and the programs above feel too risky. |
| Eden | $329/mo (tirzepatide) | 3-month minimum | Flat $329/mo for compounded tirzepatide. Note: Eden's compounded semaglutide product is an oral troche. Verify which formulation their tirzepatide uses before enrolling; oral vs injectable matters for absorption. |
Programs not listed above also offer compounded tirzepatide but at higher total cost: Form Health ($324/mo all-in, includes board-certified obesity physicians), Hone Health ($185/mo membership with medication cost separate, men's hormone focus), Push Health ($200/mo estimated, marketplace model where you source your own pharmacy), Lifeforce ($473/mo, longevity stack), and Lindora ($638/mo, in-clinic California only).
Why tirzepatide costs more than compounded semaglutide
Tirzepatide is a dual GIP/GLP-1 agonist; semaglutide is a single GLP-1 agonist. The manufacturing cost for compounded tirzepatide is higher, and the active pharmaceutical ingredient sourced by 503A compounding pharmacies reflects that. At programs that price by molecule, the gap runs $100 to $150 a month: Medvi charges $120 more for tirzepatide than semaglutide; Eden charges $120 more. Mochi's flat-rate model eliminates that differential because the program prices by membership tier, not by API cost.
The weight loss data favors tirzepatide. SURMOUNT-1 showed roughly 21% mean weight loss at the maximum dose versus roughly 15% for semaglutide in STEP-1. The direct head-to-head, SURMOUNT-5, favored tirzepatide at every dose comparison. Whether the difference justifies the $100-plus monthly premium depends on your starting weight, out-of-pocket tolerance, and how long you plan to stay on treatment. See the full drug comparison for the trial data side by side.
The regulatory risk this list carries
Compounded tirzepatide has more legal exposure than compounded semaglutide in 2026. The FDA declared the tirzepatide shortage resolved in early 2025. Under FDA compounding policy, 503A pharmacies can compound bulk API versions of drugs on the shortage list; once off the list, that exception narrows. Programs are operating under personalization-claim exceptions and remaining pathways, but the legal footing is weaker than it was in 2024.
Eli Lilly has filed litigation against compounding pharmacies dispensing tirzepatide. Mochi Health and Found are among programs named in public court records as of 2025. Both continue to operate compounded tirzepatide programs. If a court order or settlement forces a program to stop dispensing mid-treatment, the alternatives are branded Zepbound (more expensive without insurance) or switching to compounded semaglutide.
The practical implication: if you are starting a 6-month or longer tirzepatide course, ask the program directly about their contingency plan for regulatory disruption before you enroll.
Branded tirzepatide is Zepbound (for weight management) and Mounjaro (for type 2 diabetes), both FDA-approved products from Eli Lilly. Compounded tirzepatide uses the same active molecule prepared by a 503A pharmacy under a prescriber's order. It is not FDA-approved as a drug product. Quality and consistency depend on the pharmacy's testing practices and API sourcing. See our compounded vs FDA-approved explainer for the full framework; the same principles apply to tirzepatide.
FAQ
Is $178 a month really the cheapest compounded tirzepatide available?
$178/mo is the cheapest verified all-in price in our chart for an injectable compounded GLP-1 program that includes tirzepatide and does not impose a dose-tier price increase at maintenance. Ivim Health lists $175/mo but requires a 4-month minimum. If you find a lower advertised price elsewhere, the key checks are: does the price change at a higher dose, is medication included or billed separately, and what is the lock-in term?
Should I choose compounded tirzepatide or compounded semaglutide on cost?
On cost alone, compounded semaglutide is cheaper at most programs. The gap is roughly $100 to $150 a month. Whether tirzepatide's higher trial weight loss (roughly 21% vs 15% in registration trials) justifies that extra cost depends on your starting weight and treatment goals. At a $120/mo difference over 12 months, tirzepatide costs roughly $1,440 more. See the drug comparison page for the full trial data side by side.
What happens if my program is forced to stop compounded tirzepatide?
If regulatory action forces a program to stop dispensing compounded tirzepatide, your options are: switch to compounded semaglutide at the same program (if available), pursue branded Zepbound through insurance or a manufacturer savings program, or transfer to another program. Stopping GLP-1 treatment mid-course commonly results in weight regain. Build a contingency plan with your prescriber before you start.
References
Programs mentioned in this article
